Ashland Inc. filings document formal disclosures for a public specialty ingredients company, including Form 8-K reports furnished for quarterly and annual results, outlook updates and Regulation FD materials. These filings connect reported operating performance to segment conditions, cost pressures, productivity issues and cash-flow measures used in company financial releases.
The filing record also includes governance and compensation disclosures, including definitive proxy materials, annual meeting voting results, director elections, auditor ratification, advisory executive-compensation votes, board-composition changes and equity-award arrangements under the company’s incentive compensation plan.
An SEC Form 3 for Ashland Inc. lists Allen A. Spizzo as a director and serves as his initial statement of insider status at the company. No equity transactions or holdings are reported in this Form 3, and a related Power of Attorney is attached as an exhibit.
Thomas Peter T, a director of Ashland Inc., reported ownership of 4,500 shares of Common Stock, held directly, as of 2026-07-27. A remark notes that Exhibit 24 Power of Attorney is attached in connection with this ownership report.
Ashland Inc. reports a significant shareholder position by Leon G. Cooperman. Cooperman, a United States citizen and Managing Member of Omega Associates, L.L.C., may be deemed the beneficial owner of 2,915,000 shares of Ashland common stock held directly by Omega Capital Partners, L.P.
These shares represent approximately 6.4% of Ashland’s common stock, based on 45,793,370 shares outstanding as of June 30, 2026, as reported in Ashland’s Form 10‑Q filed July 29, 2026. Cooperman has sole voting and sole dispositive power over the 2,915,000 shares and no shared voting or dispositive power.
Ashland Inc. entered into a Fifth Amendment to its Receivables Purchase Agreement on July 30, 2026 with PNC Bank, PNC Capital Markets and other parties. The accounts receivable securitization facility now provides commitments of up to $70 million.
The amendment extends the facility’s termination date to July 28, 2028, replacing a prior schedule under which commitments of up to $80 million applied from September 13, 2024 through December 31, 2024 and up to $70 million from January 1, 2025 through September 11, 2026. Related disclosures describe this as a direct financial obligation and an obligation under an off-balance sheet arrangement.
Vanguard Portfolio Management LLC, together with certain affiliates, reports beneficial ownership of 2,482,141 shares of Ashland Inc common stock on a Schedule 13G. This represents 5.42% of the outstanding class as of June 30, 2026.
Vanguard Portfolio Management has sole voting power over 19,303 shares and sole dispositive power over all 2,482,141 shares, with no shared voting or dispositive power. The position includes shares held by Vanguard funds and managed accounts where these entities exercise dispositive and/or voting power; no other individual person is reported to have an interest exceeding 5% of the class through these holdings.
Ashland Inc. SVP and CTO Osama M. Musa exercised 9,793 Stock Appreciation Rights at an exercise price of $57.96 per share, eliminating this SAR position. The exercise was settled on a net-share basis, resulting in the acquisition of 1,267 common shares and increasing his direct holdings to 30,806 shares. The SARs were granted under the Ashland Inc. 2021 Omnibus Incentive Compensation Plan and the transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on February 26, 2026.
Ashland Inc. reported for the quarter ended June 30, 2026 sales of $497 million, up from $463 million a year earlier. Gross profit rose to $170 million from $132 million. Operating income was $43 million versus a prior-year operating loss of $708 million, which had included $706 million of goodwill impairment. Income from continuing operations was $41 million compared with a loss of $719 million, and after a $25 million loss from discontinued operations, net income was $16 million, or $0.35 per diluted share, versus a net loss of $742 million, or $(16.21) per share.
For the nine months ended June 30, 2026, sales were $1.365 billion versus $1.347 billion in 2025. Net income was $20 million (earnings of $0.43 per share) compared with a loss of $877 million (loss of $18.85 per share). Cash flows from continuing operations provided $295 million, up from $94 million, helping increase cash and cash equivalents to $440 million at June 30, 2026 from $215 million at September 30, 2025. Long-term debt was $1.374 billion, and the consolidated net leverage ratio was 2.3 under a new $500 million five-year revolving credit facility, with $496 million of capacity available.
Legacy and restructuring items remain significant. Discontinued operations reflected asbestos-related and other legacy losses of $25 million in the quarter. Ashland increased asbestos litigation reserves to $262 million for Ashland and $183 million for Hercules, partly offset by insurance receivables of $103 million and $53 million, respectively. Restructuring-related severance expense was $4 million for the nine months, and accelerated depreciation for plant optimization was $4 million, both below prior-year levels, while no new goodwill impairments were recorded.
Ashland Inc. senior vice president Alessandra Faccin reported equity award activity. On 2026-07-27, 3,215 Restricted Stock Units were converted into an equal number of Ashland common shares at an indicated price of $66.38 per share. Of these shares, 884 were withheld to cover tax liabilities under Ashland’s shareholder-approved incentive plan. Following the RSU transaction, her directly held balance of equity awards tied to Ashland common stock totaled 9,646 units, including amounts acquired in lieu of cash dividends. Footnotes also note a prior grant of 15,234 RSUs on July 25, 2024, vesting 20% on July 25, 2025, 20% on July 25, 2026, and 60% on July 25, 2027, conditioned on continuous employment.
Ashland Inc. appointed Peter Thomas and Allen Spizzo as independent directors effective July 27, 2026, with initial terms running until the 2027 annual meeting of stockholders. With these appointments, the board temporarily expands to eleven members, with a planned reduction to ten members at the 2027 meeting.
The company also created a Capital Allocation Advisory Committee, initially with five voting directors, chaired by Scott A. Tozier with Peter Thomas as vice chair and CEO Guillermo Novo as a non-voting member, to support capital allocation strategy. Ashland entered into a Cooperation Agreement with Ancora Holdings Group and an investor group that includes voting commitments, standstill and mutual non-disparagement provisions for a defined standstill period tied to upcoming annual meeting cycles, plus a replacement-director right if the investor group maintains at least 1.5% beneficial ownership.
Ashland Inc. reported third‑quarter fiscal 2026 sales of $497 million, up seven percent from $463 million a year earlier, with volumes rising six percent across all business units. Net income was $16 million, versus a loss of $742 million, and income from continuing operations was $41 million, or $0.89 per diluted share.
Adjusted EBITDA was $109 million with a 21.9 percent margin, down four percent from $113 million as Life Sciences and Personal Care growth was more than offset by lower Specialty Additives and Intermediates earnings and the lingering impact of earlier lower production rates and inflationary cost pressures. Cash from operations reached $121 million, ongoing Free Cash Flow was $103 million, and net leverage stood at 2.4x.
The company reaffirmed full‑year fiscal 2026 sales guidance of $1,835–$1,870 million and Adjusted EBITDA guidance of $385–$400 million, while trimming its adjusted EPS growth outlook to low‑to‑mid single‑digit growth due to a higher tax rate from unfavorable discrete items.